Literature DB >> 21349414

The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.

Ben Lawrence1, Bjorn I Gustafsson, Mark Kidd, Marianne Pavel, Bernhard Svejda, Irvin M Modlin.   

Abstract

Chromogranin A, although it exhibits limitations, is currently the most useful general tumor biomarker available for use in the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (NETs). The value of the chromogranin A lies in its universal cosecretion by the majority of neuroendocrine cells that persists after malignant transformation. Clinicians aware of the physiologic role of chromogranin A and its secretion in a variety of non-NET-related pathologic conditions can use this protein as a moderately effective tumor biomarker in the management of GEP-NETs.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21349414     DOI： 10.1016/j.ecl.2010.12.001

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN： 0889-8529            Impact factor:   4.741


  55 in total

1.  The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.

Authors:  I M Modlin; M Kidd; L Bodei; I Drozdov; H Aslanian
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

2.  Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin.

Authors:  Wieland H Sommer; Felix Ceelen; Xabier García-Albéniz; Philipp M Paprottka; Christoph J Auernhammer; Marco Armbruster; Konstantin Nikolaou; Alexander R Haug; Maximilian F Reiser; Daniel Theisen
Journal:  Eur Radiol       Date:  2013-06-28       Impact factor: 5.315

3.  Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1.

Authors:  Mark A Lewis; Geoffrey B Thompson; William F Young
Journal:  World J Surg       Date:  2012-06       Impact factor: 3.352

4.  Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.

Authors:  Laura H Tang; Brian R Untch; Diane L Reidy; Eileen O'Reilly; Deepti Dhall; Lily Jih; Olca Basturk; Peter J Allen; David S Klimstra
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

Review 5.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

6.  Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.

Authors:  Amir Sabet; Alexander R Haug; Collin Eiden; Christoph J Auernhammer; Birgit Simon; Peter Bartenstein; Hans J Biersack; Samer Ezziddin
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-04-15

Review 7.  Hormone secreting gastro-entero-pancreatic neuroendocrine neoplasias (GEP-NEN): When to consider, how to diagnose?

Authors:  Christian Fottner; Martina Ferrata; Matthias M Weber
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

8.  Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.

Authors:  Yash Somnay; Kevin Simon; April D Harrison; Selvi Kunnimalaiyaan; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Anticancer Drugs       Date:  2013-01       Impact factor: 2.248

9.  Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.

Authors:  S Chiloiro; F Lanza; A Bianchi; G Schinzari; M G Brizi; A Giampietro; V Rufini; F Inzani; A Giordano; G Rindi; A Pontecorvi; L De Marinis
Journal:  Endocrine       Date:  2017-05-31       Impact factor: 3.633

10.  Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.

Authors:  Monica Ter-Minassian; Jennifer A Chan; Susanne M Hooshmand; Lauren K Brais; Anastassia Daskalova; Rachel Heafield; Laurie Buchanan; Zhi Rong Qian; Charles S Fuchs; Xihong Lin; David C Christiani; Matthew H Kulke
Journal:  Endocr Relat Cancer       Date:  2013-03-22       Impact factor: 5.678
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.